Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3B P/E 10.96 EPS this Y -133.30% Ern Qtrly Grth -
Income -131.04M Forward P/E 31.45 EPS next Y 500.00% 50D Avg Chg -7.00%
Sales 274.1M PEG 14.47 EPS past 5Y -57.25% 200D Avg Chg -15.00%
Dividend N/A Price/Book 3.02 EPS next 5Y -76.72% 52W High Chg -57.00%
Recommedations 1.80 Quick Ratio 10.19 Shares Outstanding 132.83M 52W Low Chg 11.00%
Insider Own 1.30% ROA -1.56% Shares Float 82.62M Beta 0.03
Inst Own 104.81% ROE -19.04% Shares Shorted/Prior 7.13M/5.12M Price 11.95
Gross Margin 44.03% Profit Margin -47.81% Avg. Volume 2,999,532 Target Price 10.42
Oper. Margin -31.28% Earnings Date Aug 5 Volume 6,578,673 Change 8.34%
About Maravai LifeSciences Holdings,

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings, News
05/17/24 Maravai (MRVI) Advances in RNA Research With New Collaboration
05/13/24 TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
05/10/24 Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/09/24 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2024 Earnings Call Transcript
05/09/24 Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
05/09/24 Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: ...
05/09/24 Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript
05/08/24 Maravai LifeSciences Reports First Quarter 2024 Financial Results
04/30/24 TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
04/18/24 TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
04/10/24 Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
06:48 AM Should You Sell Maravai LifeSciences (MRVI)?
03/12/24 Maravai LifeSciences Announces March 2024 Investor Conference Schedule
02/24/24 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Released Its Annual Results And Analysts Are Updating Their Estimates
02/23/24 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call Transcript
02/23/24 Q4 2023 Maravai LifeSciences Holdings Inc Earnings Call
02/22/24 Maravai LifeSciences (MRVI) Q4 2023 Earnings Call Transcript
02/22/24 Maravai LifeSciences Holdings Inc (MRVI) Faces Net Loss in 2023 Despite Revenue Outperformance
02/22/24 Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
02/21/24 TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
MRVI Chatroom

User Image StockInvest_us Posted - 1 day ago

Signal alert: $MRVI - Overbought Trend Short (Overvalued) https://stockinvest.us/l/qmmmEAkEwt

User Image Stock_Titan Posted - 6 days ago

$MRVI TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center https://www.stocktitan.net/news/MRVI/tri-link-bio-technologies-collaborates-with-johns-hopkins-university-6fe6zx5vjzls.html

User Image SadyK189 Posted - 6 days ago

Top Stocks to watch next week 2 / 3: $XBP Initially alerted at 2.05. Still looking good on daily chart. 2.8 - 3.15 is acting as strong support zone. Next key level to test is 4.65 - 4.95. $CDNA looking good on daily chart. key support at 11.80 - 12.60. Looking good to test next key level at 16.10 - 16.80. $RENT looking good on daily chart. However, facing stiff resistance at 18 - 18.80 zone. Once it clears this zone, we can expect it to test 20.7 - 21.3 zone soon. Overall, it has potential of $27+. $MRVI Generally moves slowly and steadily. Looking good on 4hours chart. Key support at 8.8 - 9.25. We can expect $12+ in it. $SWIN looking strong on daily chart. It has formed key support zone at 15.75 - 16.10. Looking good to test next key level at 21.70 - 22.50. Overall, it has potential of $29+

User Image Stock_Titan Posted - 1 week ago

$MRVI Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule https://www.stocktitan.net/news/MRVI/maravai-life-sciences-announces-may-and-june-2024-investor-hdxhbm3jeq4q.html

User Image AC_TRADER Posted - 1 week ago

Daily recap of actionable TRADE IDEAS mentioned to subscribers $MRVI amazing SWING - delivered all Targets and ended up hugely +46% !

User Image DonCorleone77 Posted - 1 week ago

$MRVI Maravai Lifesciences backs FY24 revenue view $265M-$285M, consensus $271.81M Backs FY24 adjusted EBITDA margin view 23%-25%. "We are thrilled to add Lonza to our growing network of top-tier global providers to bring CleanCap and all our technologies to the global mRNA therapeutics market. We remain confident in our long-term opportunities, the fundamental strength of our end markets, and the value we provide our customers for life-changing development of drug therapies, diagnostics and novel vaccines," Martin concluded.

User Image DonCorleone77 Posted - 1 week ago

$MRVI Maravai Lifesciences reports Q1 adjusted EPS (2c), consensus (2c) Reports Q1 revenue $64.18M, consensus $60.55M. "We had a solid start to the year, and I am proud of the drive and intensity from our strengthened commercial team, which delivered additional wins and expanded relationships among biotech, biopharma, CDMO, and academic customers," said Trey Martin, Chief Executive Officer of Maravai. "We are executing on our return to growth strategy, bringing new innovations, and increased manufacturing capacity to our customers, moving us closer to our goal of long-term sustainable growth."

User Image epsguid Posted - 1 week ago

$MRVI reported a loss of $0.09, consensus was ($0.06) via @eWhispers #epsmiss http://eps.sh/d/mrvi

User Image Stock_Titan Posted - 1 week ago

$MRVI Maravai LifeSciences Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/MRVI/maravai-life-sciences-reports-first-quarter-2024-financial-5jzj2i9c2yyh.html

User Image DonCorleone77 Posted - 04/30/24

$MRVI Maravai Lifesciences subsidiary, Lonza enter license and supply pact for capping TriLink BioTechnologies, a Maravai LifeSciences company, has signed a non-exclusive license and supply agreement with Lonza. According to the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3'OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza's global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

User Image Stock_Titan Posted - 04/30/24

$MRVI TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology https://www.stocktitan.net/news/MRVI/tri-link-bio-technologies-r-and-lonza-enter-into-non-exclusive-f5xm8v0yiuxr.html

User Image Stock_Titan Posted - 1 month ago

$MRVI TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production https://www.stocktitan.net/news/MRVI/tri-link-bio-technologies-r-announces-new-san-diego-facility-for-y37fkfbldm3i.html

User Image Stock_Titan Posted - 1 month ago

$MRVI Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024 https://www.stocktitan.net/news/MRVI/maravai-life-sciences-to-host-earnings-conference-call-on-wednesday-bhy29yjcdniz.html

User Image DonCorleone77 Posted - 1 month ago

$MRVI Craig-Hallum bullish on Maravai Lifesciences, initiates with a Buy Craig-Hallum initiated coverage of Maravai Lifesciences with a Buy rating and $15 price target. The firm believes shares of Maravai are poised for a rebound and thinks investors should add the stock to their portfolios. FY23 was a challenging year on multiple fronts as COVID-related revenues fell off, pharma/biotech funding dried up resulting in slower drug development and a reprioritization of pipelines. The funding environment is improving, and pharma/biotech companies are moving ahead with development plans resulting in increasing demand in the gene editing, cell and gene therapy and biologic drug manufacturing end markets. Craig-Hallum believes Maravai Lifesciences provides investors with the opportunity to participate in each of these high-growth markets.

User Image ApeTownBanger Posted - 1 month ago

$MRVI

User Image DitchRider Posted - 03/28/24

$MRVI

User Image TrendsetterTrading Posted - 03/24/24

$MRVI $8.50 breakout looking solid for continuation higher ⬆️

User Image RollingDollar Posted - 03/23/24

$MRVI

User Image dojidad Posted - 03/23/24

$MRVI It's like a groundhog popping its head out and looking for his shadow. Will it be Spring and he'll emerge? Or will winter continue and he goes back underground. He's looking around as we speak......

User Image josephfuller Posted - 03/23/24

$MRVI CATX PEOPLE IT’S THE NEXT RADIONUCLIDE!.

User Image RiskVsReward Posted - 03/23/24

$MRVI Watch this as we get into key support and resistance levels here. 🚨

User Image dixiebull Posted - 03/23/24

$MRVI nice grind and testing the 200ma, I like that the 50 is curling up as well. Possible longer term hold. Day trade can take it to 10.

User Image GSP Posted - 03/20/24

I like the look of this $MRVI chart. Keep it on your radar.

User Image GSP Posted - 03/20/24

Trading Watch List Video for March 21st (con't): $TKO $NNOX $MRVI $CXAI $GOEV Watch here: https://greatstockpix.com/march-21st-day-trading-watch-list/

User Image GSP Posted - 1 month ago

$MRVI is pretty coiled here. It's on our watch list for tomorrow.

User Image TraderIsaac Posted - 1 month ago

$MRVI Looks even better now.

User Image GSP Posted - 1 month ago

Day Trading Watch List Video for March 20th: $SPY $CGC $NNOX $MRVI $CDLX Watch here: https://greatstockpix.com/march-20th-day-trading-watch-list/

User Image GSP Posted - 2 months ago

$MRVI makes our watch list for Tuesday.

User Image GSP Posted - 2 months ago

Day Trading Watch List Video for March 19th (con't): $MRVI $PIXY $LICY $LSF $CRDF Watch here: https://greatstockpix.com/march-19th-day-trading-watch-list/

User Image ApeTownBanger Posted - 2 months ago

$MRVI come on, lets get an offer for 65$ and get over with it.

Analyst Ratings
Baird Outperform May 9, 24
Craig-Hallum Buy Apr 10, 24
RBC Capital Outperform Feb 23, 24
Stifel Buy Feb 23, 24
B of A Securities Buy Dec 12, 23
Goldman Sachs Neutral Nov 9, 23
Morgan Stanley Overweight Nov 9, 23
Morgan Stanley Overweight Aug 9, 23
Deutsche Bank Buy Aug 8, 23